Buy Inspra

Inspra

What is Inspra?

Inspra is a prescription pill that contains the active ingredient eplerenone, a selective aldosterone antagonist. It belongs to the Heart & Blood Pressure therapeutic class and is marketed in the United Kingdom by the manufacturer Bristol-Myers Squibb. The medication is available in two strengths: 25 mg and 50 mg tablets. Inspra is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of hypertension and for reducing the risk of cardiovascular death in patients with chronic heart failure following a myocardial infarction.

How Inspra Works in the Body

Eplerenone blocks the binding of aldosterone-a hormone produced by the adrenal glands-to its mineralocorticoid receptors in the kidneys, heart, and blood vessels. By antagonising these receptors, Inspra reduces sodium reabsorption and potassium excretion, leading to modest diuresis and a decrease in blood volume. The reduction in sodium and fluid load lowers arterial pressure, while the blockade of aldosterone’s profibrotic effects helps prevent adverse cardiac remodeling in heart-failure patients.

Key pharmacologic points:

• Onset of action: Blood-pressure-lowering effects may be observed within a few days, but full therapeutic benefit often requires several weeks.
• Peak effect: Approximately 2-4 weeks after initiating therapy.
• Duration: The drug’s half-life is about 4-6 hours, but the prolonged receptor blockade confers lasting clinical effects.
• Metabolism: Eplerenone is metabolised primarily by the liver (CYP3A4) and eliminated via the kidneys; dose adjustments may be required in renal impairment.

Conditions Treated by Inspra

Hypertension

• Inspra is indicated for adults with high blood pressure when additional control is needed beyond first-line agents (e.g., ACE inhibitors, calcium-channel blockers).

Chronic Heart Failure (post-myocardial infarction)

• In patients with left-ventricular systolic dysfunction after a heart attack, Inspra reduces the risk of cardiovascular death and hospitalization for heart failure.

Both indications are supported by the MHRA’s product licence and are reflected in NHS prescribing guidance.

Evidence-Based Off-Label Uses

Current peer-reviewed literature provides limited evidence for off-label applications of eplerenone. Some small studies have explored its role in:

• Primary aldosteronism: Low-dose eplerenone may be used to control blood pressure while awaiting definitive surgery, but this remains a specialist decision.
• Diabetic nephropathy: Preliminary data suggest potential renal protective effects, yet robust clinical trials are lacking.

Disclaimer: Off-label use of Inspra requires careful medical supervision and an individualized risk-benefit assessment.

Who Should (Not) Use Inspra?

Absolute Contraindications

• Known hypersensitivity to eplerenone or any excipients in the tablet.
• Severe hyperkalaemia (serum potassium > 5.5 mmol/L).
• Concomitant use of potassium-sparing diuretics (e.g., spironolactone, amiloride) or potassium supplements when serum potassium is already elevated.
• End-stage renal disease (eGFR < 15 mL/min/1.73 m²).

Relative Contraindications

• Moderate renal impairment (eGFR 15-30 mL/min/1.73 m²): dose reduction and close monitoring are advised.
• Hepatic impairment: use with caution, monitor for signs of fluid overload.
• Pregnancy (Category D) and breastfeeding: eplerenone crosses the placenta and is excreted in breast milk; it should be avoided unless the potential benefit justifies the risk.

Special Populations

• Elderly: May have reduced renal function; start at the lower dose (25 mg) and titrate slowly.
• Patients with diabetes: Monitor potassium and renal function closely, as hyperkalaemia risk may be higher.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Hyperkalaemia - most frequent, may be asymptomatic or present with muscle weakness.
• Dizziness or light-headedness - often related to blood-pressure reduction.
• Gastrointestinal discomfort - mild nausea or abdominal pain reported in ≤5 % of patients.

Serious Adverse Events

• Severe hyperkalaemia (potassium > 6.0 mmol/L) can cause cardiac arrhythmias; seek emergency care if symptoms such as palpitations or muscle paralysis occur.
• Acute kidney injury - particularly when combined with ACE inhibitors or ARBs.
• Angio-edema (rare) - may present as swelling of the face, lips, or throat.

Drug Interactions

• ACE inhibitors / ARBs - combined use increases the risk of hyperkalaemia and renal dysfunction; monitor electrolytes and renal function.
• Potassium supplements or salt substitutes - can precipitate hyperkalaemia; avoid unless medically supervised.
• Non-steroidal anti-inflammatory drugs (NSAIDs) - may reduce renal clearance of eplerenone, raising potassium levels.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) - can increase eplerenone plasma concentrations; dose adjustment or alternative therapy may be required.

Food and Lifestyle Interactions

• Dietary potassium - high-potassium foods (bananas, oranges, leafy greens) should be consumed in moderation, especially if renal function is impaired.
• Alcohol - does not directly interact, but excessive intake can worsen blood-pressure control.
• Driving - dizziness may affect ability to operate machinery; use caution until you know how the medication affects you.

If specific interaction data for Inspra is limited, patients should inform their healthcare provider of all medicines, supplements, and herbal products before initiating therapy.

How to Take Inspra

• Standard dosing for hypertension: 50 mg once daily, taken with or without food.
• Standard dosing for post-MI heart failure: Start with 25 mg once daily; after 4-6 weeks, may increase to 50 mg once daily if serum potassium ≤5.0 mmol/L and renal function is stable.

Special population adjustments

• Renal impairment (eGFR 30-60 mL/min/1.73 m²): Initiate at 25 mg once daily; monitor potassium and creatinine within 1-2 weeks.
• Elderly: Consider starting at 25 mg regardless of indication.

Administration tips

• Swallow the tablet whole; do not crush or chew.
• Store at room temperature, away from moisture and heat.
• If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double-dose.

Overdose

• Symptoms may include severe hyperkalaemia, hypotension, and dizziness.
• Seek immediate medical attention; treatment focuses on stabilising cardiac membranes (calcium gluconate) and lowering serum potassium (insulin-glucose, sodium polystyrene sulfonate, or dialysis).

Discontinuation

• No tapering is required for eplerenone; however, abrupt cessation may lead to a rebound increase in blood pressure. Follow up with a clinician for alternative therapy.

Monitoring and Follow-Up

• Serum potassium: Check within 1-2 weeks after initiating therapy or after any dose change; then every 3-6 months.
• Renal function (serum creatinine, eGFR): Baseline measurement before starting, repeat at 1 month, then periodically based on clinical status.
• Blood pressure: Monitor weekly until target is reached, then at routine clinic visits.
• Electrocardiogram (ECG): Consider if severe hyperkalaemia develops.

Patients should contact their healthcare provider promptly if they experience muscle weakness, palpitations, or a sudden rise in blood pressure.

Storage and Handling

• Keep the tablets in the original blister pack until use.
• Store at 15 °C to 30 °C (room temperature), protected from light and moisture.
• Do not use tablets after the expiry date printed on the pack.
• Dispose of unused medication via a local pharmacy take-back scheme or follow NHS guidelines for safe drug disposal.

Medication-Specific Glossary

Aldosterone Antagonist

A drug that blocks the action of aldosterone at mineralocorticoid receptors, reducing sodium retention and potassium loss.

Hyperkalaemia

Elevated potassium levels in the blood, which can impair cardiac electrical activity and cause arrhythmias.

eGFR (estimated Glomerular Filtration Rate)

A calculated measure of kidney function used to adjust medication dosing and assess renal health.

Mineralocorticoid Receptor

A cellular receptor that binds aldosterone, influencing fluid and electrolyte balance.

Cardiac Remodeling

Structural changes in the heart muscle following injury (e.g., myocardial infarction) that can lead to heart failure.

Medical Disclaimer

This article provides educational information about Inspra and is not a substitute for professional medical advice. Treatment decisions, including the use of Inspra for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.